Novartis AG
NVS
$164.70
$2.031.25%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.98B | 14.39B | 13.65B | 12.86B | 11.94B |
| Total Depreciation and Amortization | 4.74B | 4.73B | 4.64B | 4.59B | 4.60B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.48B | 2.98B | 3.77B | 3.03B | 2.89B |
| Change in Net Operating Assets | -3.06B | -1.03B | -1.27B | -1.49B | -1.81B |
| Cash from Operations | 19.14B | 21.07B | 20.79B | 19.00B | 17.62B |
| Capital Expenditure | -1.55B | -1.50B | -1.46B | -1.39B | -1.37B |
| Sale of Property, Plant, and Equipment | 13.00M | 59.00M | 59.00M | 95.00M | 86.00M |
| Cash Acquisitions | -2.92B | -2.18B | -2.15B | -3.78B | -4.02B |
| Divestitures | -88.00M | 85.00M | 156.00M | 141.00M | 107.00M |
| Other Investing Activities | -338.00M | -2.27B | -1.92B | -1.35B | -2.32B |
| Cash from Investing | -4.88B | -5.81B | -5.32B | -6.28B | -7.51B |
| Total Debt Issued | 6.67B | 1.52B | 5.05B | 7.24B | 7.91B |
| Total Debt Repaid | -4.24B | -2.48B | -2.99B | -4.53B | -3.52B |
| Issuance of Common Stock | 27.00M | 23.00M | 26.00M | 31.00M | 30.00M |
| Repurchase of Common Stock | -9.21B | -10.49B | -11.05B | -9.95B | -8.33B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -7.82B | -7.82B | -7.82B | -7.75B | -7.62B |
| Other Financing Activities | -294.00M | -298.00M | -363.00M | -173.00M | -207.00M |
| Cash from Financing | -14.87B | -19.55B | -17.14B | -15.13B | -11.74B |
| Foreign Exchange rate Adjustments | 576.00M | 226.00M | 424.00M | 8.00M | -298.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -24.00M | -4.05B | -1.25B | -2.40B | -1.93B |